Search

Your search keyword '"Xu, Jian-Ming"' showing total 205 results

Search Constraints

Start Over You searched for: Author "Xu, Jian-Ming" Remove constraint Author: "Xu, Jian-Ming" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
205 results on '"Xu, Jian-Ming"'

Search Results

14. Supplementary Table 5 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

15. Supplementary Table 2 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

16. Supplementary Table 4 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

17. Supplementary Table 6 and Table 7 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

18. Supplementary Table 1 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

19. Supplementary Table 3 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

31. Proteomic profiling identifies signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer

32. Chinese Consensus Report on Family-BasedHelicobacter pyloriInfection Control and Management (2021 Edition)

35. Identification of Crucial Genes and Related Transcription Factors in Ulcerative Colitis

37. Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms

38. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 trial (ORIENT-2)

43. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial

44. Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

45. Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.

46. S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.

47. A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).

Catalog

Books, media, physical & digital resources